There is one detail that needs to be noted. Among pharmaceutical distribution companies, the gross profit margins of Sinopharm and Shanghai Pharmaceuticals that have sesame distribution licenses are higher than other companies
Not only in the circulation industry, but also in the pricing process of sesame pharmaceutical companies, There is also a certain gap between sesame drugs and ordinary pharmaceutical companies.
For example, in the field of anesthetics, they can be divided into narcotic analgesics and general anesthetics according to the pricing mechanism. Narcotic analgesics (such as fentanyl, morphine, etc.) are priced uniformly, and the ex-factory price and wholesale price of drugs are uniformly determined by the regulatory authorities.
Common anesthetics (such as sevoflurane, propofol , etc.) are mainly priced by market bidding.
Due to the special nature of anesthetics, if you want to enter this track, you require a high entry threshold, that is, a production license.
This is the moat.
Currently, there are only 1-2 approved designated manufacturers of anesthetic raw materials, 1-3 designated manufacturers of single preparations, and 1-7 designated manufacturers of compound preparations . Compared with chemical drugs, there are usually about 10 generic drugs. Judging from the competitive landscape, this track is indeed relatively easy and has less competitive pressure. Throughout the history of
, it can be roughly divided into two stages: the first stage of
, from 2008 to 2014 (original products grew steadily); the second stage of
, from 2014 to the present (renewed efforts after the product adjustment period
Before analyzing Enhua Pharmaceutical's operating conditions at each stage, let's first take a look at the segment it is in - central nervous system drugs.
Central nervous system drugs are mainly divided into two categories:
First, inhibitory drugs. Drugs: mainly include sedative-hypnotics, antipsychotic drugs, anti-epileptic drugs, anticonvulsant drugs, anti-Parkinson's drugs, and analgesics.
Secondly, stimulant drugs: mainly central nervous system stimulants. Among the total consumption of neurological drugs, the United States accounts for 49%, Europe and Japan account for 26% and 9% respectively. my country only accounts for 3% of the total global consumption.
Just by comparing this data, we can see this track. How much room is there for growth? Basically, the use of central nervous system drugs is positively related to the degree of economic development.
China’s economy is about the same as that of the United States, and its population is four times that of the United States, but the consumption of such drugs is so low. - It can be seen that the domestic central nervous system drug industry is still in its infancy compared with foreign countries.
Based on the above data, there is no need to be suspicious of the future ceiling, and you may even have to pay attention to the possibility of ultra-rapid growth in certain stages.
Amex predicts that by 2025, China's central nervous system disease market will reach or even exceed 100 billion yuan.
Enhua Pharmaceutical's main focus is on central nervous system drugs such as narcotics and psychiatric drugs
. Let's look at them separately:
Let's first look at anesthetics - anesthetics, their main function is to inhibit the central nervous system , causing patients to show symptoms such as loss of consciousness and pain , muscle relaxation, etc.
At present, the size of my country's anesthetic drug market is close to 20 billion yuan, with an average growth rate of about 20%.
Anesthetic drugs are mainly divided into four categories according to their different functions: general anesthetics, local anesthetics, narcotic analgesics, and muscle relaxants. Category. In general surgery, different anesthesia methods are selected according to the patient's condition.
Among them, analgesics have the highest market share, reaching 44%, followed by general anesthesia (40%) and muscle relaxants (12%). , local anesthetics (4%). The control of
is relatively strict, so there are relatively few participating companies. Renfu Pharmaceutical is the main manufacturer in this track.
So how effective is Enhua Pharmaceutical in this area?
predicts the follow-up, and listening to the next chapter’s analysis
does not constitute any investment advice. The stock market has risks, so you need to be cautious when entering the market.
Previous article review:
